Clinical Trials Directory

Trials / Sponsors / ARCA Biopharma, Inc.

ARCA Biopharma, Inc.

Industry · 12 registered clinical trials.

StatusTrialPhaseStarted
CompletedAssessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19
Covid19
Phase 2 / Phase 32020-12-10
CompletedGenetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Fail
Current or Recent History of Atrial Fibrillation
Phase 22014-04-01
UnknownStudy of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery
Heart Disease
Phase 22013-01-01
TerminatedPhase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore
Acute Ischemic Stroke
Phase 22007-06-01
SuspendedSafety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
Colon Cancer
Phase 1 / Phase 22006-12-01
TerminatedStudy of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
Arterial Occlusive Diseases
Phase 32006-04-01
CompletedSafety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters
Thrombosis, Venous Thrombosis, Catheter Occlusion
Phase 32006-01-01
CompletedSafety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
Thrombosis, Venous Thrombosis
Phase 32005-09-01
CompletedAnticoagulation With rNAPc2 to Eliminate MACE/TIMI 32
Coronary Disease
Phase 22005-06-01
CompletedStudy of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg A
Arterial Occlusive Diseases
Phase 32005-04-01
CompletedAlfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Phase 22003-06-01
CompletedTrial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices
Catheters, Indwelling
Phase 2—